Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. Linagliptin was developed by Boehringer Ingelheim Pharma G.M.B.H. & Co. K.-G..
The API has now reached off-patent status, after being launched in 2011.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Linagliptin was exported from India in 2023 , with an average price over the period of $2455 /kg.
The key suppliers were MSN Laboratories, with a focus on markets in Asia Pacific.

For enquiries regarding more detailed trade data of Linagliptin and many others, contact info@pharmacheminvestor.com